Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, announces it has received EUR 800,000 as the second and last payment of a EUR 1.4 million refundable grant contract originally signed with France’s innovation agency, Oseo Innovation, in 2008.
The transaction follows the successful completion of Phase IIa clinical tolerance study of oral inecalcitol in hormone-refractory prostate cancer patients. The first payment of EUR 600,000 was received at the signature of the contract.
“This is a highly significant grant for Hybrigenics. It shows Oseo’s confidence in our product and in our ability to successfully complete clinical trials,” explained Guillaume Floch, Hybrigenics’ CFO. “The total EUR 1.4M will be reimbursed between 2012 and 2015. No interest is payable. This final payment will help fund further clinical development of inecalcitol.”
Hybrigenics Receives EUR 800,000 Payment from Oseo
News Dec 03, 2010

Read Time:
Advertisement
RELATED ARTICLES
News
Treatment with the neoantigen cancer vaccine PGV-001 following standard-of-care adjuvant therapy was well tolerated and demonstrated potential clinical benefit in patients with diverse tumor types according to a Phase 1 study. The findings were reported during the virtual AACR Annual Meeting 2021.
READ MORETo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
Advertisement